Abstract
Incidence of breast cancer (BC), particularly in younger women, has increased in last decade. About forty percent of all BC are observed in women under the age of 50 years and, accordingly, in pre-menopausal women. Luminal-like is the most common subtype. Pre-menopausal status is associated with clinical, social and psychological issues that must be addressed as part of oncology care to guarantee the best global health outcomes after treatment. This review aims to answer the most common questions on endocrine treatment in pre-menopausal women. In particular, it focuses on the decision-making process that drives the choice about ovarian function suppression, use of aromatase inhibitors, and duration of therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
